Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1.54 ^USD	+20.31%		+50.98%	-47.44%

28/06	Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	MT
28/06	Sector Update: Health Care Stocks Higher Pre-Bell Friday	MT

Eleven Biotherapeutics, Inc. Announces Resignation of Eric Furfine as Chief Scientific Officer, Effective February 5, 2016

January 22, 2016 at 03:39 am IST

On January 19, 2016, Eric Furfine notified Eleven Biotherapeutics, Inc. of his resignation as Chief Scientific Officer of the Company, effective February 5, 2016. Upon the effectiveness of his resignation, the Company expects that Mr. Furfine will join the Company's Scientific Advisory Board.

Latest news about Carisma Therapeutics, Inc.

Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	28/06	MT
Sector Update: Health Care Stocks Higher Pre-Bell Friday	28/06	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Report	28/06	MT
Sector Update: Health Care	28/06	MT
Carisma Therapeutics Debuts Moderna Collaboration With Solid Tumors Investigative Study; Shares Soar Premarket	28/06	MT
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna	28/06	CI
Carisma Therapeutics' Potential Solid Tumor Therapy Gets FDA Fast Track Designation	25/06	MT
Carisma Therapeutics, Inc. Grants FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors	25/06	CI
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte	16/05	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	02/05	CI
BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	11/04	MT
HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	02/04	MT
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	02/04	MT
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04	CI
Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors	01/04	CI
North American Morning Briefing : Stock Futures -2-	19/03	DJ
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment	14/12	MT
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy	28/11	MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	28/11	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
North American Morning Briefing : Stocks Look to -2-	06/11	DJ
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC	31/23/31	CI

Chart Carisma Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Sector

Biotechnology & Medical Research

Calendar

09/07/2024 - Stifel Cell Therapy Forum

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Carisma Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.52 USD

Average target price

7.6 USD

Spread / Average Target

+400.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CARISMA THERAPEUTICS, INC.	-47.44%	63.14M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+17.18%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-18.77%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs